ELWT Earnings

ELWT reported its earnings on 2026-05-14, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was 0, surpassing the expected 0 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following ELWT's earnings announcement on 2026-05-14, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, ELWT's stock price tends to shift by an average of 3.68% in the 10 days leading up to earnings and -5.83% in the 10 days following, providing insight into potential market.

For , analysts estimate ELWT's annual revenue to reach , while the EPS is projected at . These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ELWT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ELWT's stock price typically moves by 3.68% in the 10 days before its earnings and -5.83% in the 10 days after. For the upcoming earnings, analysts expect an EPS of and revenue of .

The earnings call presents a mixed picture: strong growth in billed and activated units and a significant increase in contracted backlog are positives. However, the increased losses, operating expenses, and lack of specific guidance on key projects like the 11,000 units and NaaS initiatives temper the optimism. The Q&A session revealed uncertainties and management's reluctance to provide detailed timelines, which could concern investors. Although there are growth opportunities, the financial health and guidance issues suggest a neutral impact on stock price over the next two weeks.